#### INTERLEUKIN GENETICS INC

Form 4 May 19, 2006

## FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

**OMB** Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

**OMB APPROVAL** 

Check this box if no longer subject to Section 16. Form 4 or

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1(b).

1. Name and Address of Reporting Person \* REILLY PHILIP R

2. Issuer Name and Ticker or Trading

Symbol

INTERLEUKIN GENETICS INC

(Check all applicable)

5. Relationship of Reporting Person(s) to

[ILI]

(Last) (First) (Middle)

(Street)

3. Date of Earliest Transaction (Month/Day/Year)

Officer (give title below)

Issuer

10% Owner \_ Other (specify

135 BEAVER STREET

05/17/2005

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check

\_X\_\_ Director

Applicable Line) \_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Filed(Month/Day/Year)

Person

WALTHAM, MA 02452

(City)	(State)	Zip) Tabl	e I - Non-D	erivative S	Securi	ties Acq	uired, Disposed o	of, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)		5. Amount of Securities Form: Direct Beneficially (D) or Owned Indirect (I) Following (Instr. 4) Reported Transaction(s)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code V	Amount	or (D)	Price	(Instr. 3 and 4)		
Common Stock	05/17/2006		M	14,000	A	\$ 0.5	24,000	D	
Common Stock	05/17/2006		S	14,000 (1)	D	\$ 5.64	10,000	D	
Common Stock	05/18/2006		M	5,500	A	\$ 0.5	15,500	D	
Common Stock	05/18/2006		S	5,500 (1)	D	\$ 5.48	10,000	D	
Common Stock							73,275	I	See Footnote

#### Edgar Filing: INTERLEUKIN GENETICS INC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of etiorDerivative Securities 3) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Am Underlying Sect (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	A or N of
Option to Buy (Common Stock)	\$ 0.5	05/17/2005		M		14,000	01/01/2000(3)	05/31/2009	Common Stock	1
Option to Buy (Common Stock)	\$ 0.5	05/18/2006		M	5,500		03/01/2000	05/31/2009	Common Stock	4

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
REILLY PHILIP R 135 BEAVER STREET WALTHAM, MA 02452	X						

# **Signatures**

/s/ Philip R.
Reilly

\*\*Signature of Reporting Person

O5/19/2006

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Pursuant to a 10b5-1 Trading Plan entered into on May 15, 2006.
- Shares are held in irrevocable trusts for the benefit of Dr. Reilly's children. Dr. Reilly disclaims beneficial ownership of these securities
- (2) and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or any other purposes.

Reporting Owners 2

#### Edgar Filing: INTERLEUKIN GENETICS INC - Form 4

g
(3) 5,000 of these shares were exercisable on 1/1/00; 8,000 shares were exercisable on 2/1/00; and 1,000 were exercisable on 3/1/00. Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, <i>see</i> Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.